NCT04673357.
Ustekinumab therapy for moderately to severely active pediatric Crohn’s disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg
Elisabeth De Greef·Esau Moreno Carmache·Harold Couchoux·Csaba Bereczki·Pauline De Bruyne·Erzsébet Szakos·Marc Schaefer·Sandhia Naik·Bartosz Korczowski·Christine Spray·Jarosław Kierkuś·Michael Melter·Tamara L Feldman·B. O. Osuntokun·Ilse Hoffman·Patrick Bontems·Lilianne Kim·Wouter Van der Borght·Monika Meglicka·Laurie S. Conklin·Otto Louis-Jacques·Orsolya Kadenczki·Antal Dezsőfi·Thomas J. Sferra·Daiki Abukawa·Tatsuki Mizuochi·Stanley A. Cohen·Denisa Pilic·Sotaro Mushiake·F. Dicső·Ulrich Baumann·Jeffrey D. Lewis·Françoise Smets·Bridget Godwin·Richard S Strauss·J Rosh·S Volger·O Adedokun·Philip Bufler·Li Deng·Katarzyna Cieslak·Katsuhiro Arai·Bess Aramakis·Efrat Broide·Elena Sitnikova·Michael Stephens·Kordian Von Cyga·Richard Russell·Dan Turner·Takashi Ishige·Dror Shouval·Anne M Griffiths·Renping Zhang·Aelita Kamalova·Tobias Wenzl·Itaru Iwama·Auguste Gaddah·Jeffrey S Hyams·Vladimir Kopeikin·Hideki Kumagai·Ekaterina Tsimbalova·Tiffany Linville·for the UNITI Jr study Group·Yigal Elenberg-Alter·Lena Woelfle·Rafeeq Muhammed·Takahiro Kudo·Sibylle Koletzo·Els Van Limbergen·Zarela Molle-Rios·Franco Torrente·Kinga Kowalska-Duplaga Piotr Landowski·Yuhki Koike